Ad hoc announcement pursuant to Art.
21.05.2024 - 06:45:03GNW-Adhoc: Idorsia announces financial results for the full year of 2023 - Adapting the company to create sustainable value. 53 LR Allschwil, Switzerland - May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year of 2023.
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland - May 21, 2024
Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year
of 2023.
Business highlights
* Sale of Idorsia Asia-Pacific operations (excluding China): Sold to Nxera
Pharma (previously known as Sosei Heptares) for a total consideration of CHF
400 million in July 2023.
* Cost reduction initiative: Delivering a 50% reduction in fixed cost at Swiss
headquarters fully effective in early 2024.
* Aprocitentan: Worldwide rights reacquired from Janssen for a conditional
consideration of CHF 306 million in September 2023.
Commercial highlights
* QUVIVIQ(TM) (daridorexant): Total net sales of CHF 31 million in 2023.
* QUVIVIQ: Expanded access and availability in the US, Canada and across
Europe.
Financial highlights FY 2023
* Net revenue FY 2023 at CHF 152 million.
* US GAAP operating expenses FY 2023 at CHF 409 million and non-GAAP operating
expenses FY 2023 at CHF 654 million.
* US GAAP operating loss FY 2023 of CHF 255 million and non-GAAP operating
loss of CHF 501 million.
Jean-Paul Clozel, MD and Chief Executive Officer, commented:
"During 2023, we made great progress with expanding the availability of QUVIVIQ
and patient access in the US, Canada, and across Europe. QUVIVIQ is rapidly
being recognized by specialists as a major advance in the field of insomnia.
PIVLAZ became a very successful drug in Japan, and regulatory submissions were
advanced for aprocitentan in the US and EU. As the development and launch of
these three products required substantial financial investments, there was a
need to lower our costs. Accordingly, we reduced our headcount and prioritized
our portfolio assets; we monetized our Asia-Pacific operations; and we began
negotiations with potential partners. All these actions have been essential to
the future of the company."
André C. Muller, Chief Financial Officer, commented:
"2023 was a year of adaptation for Idorsia. When it became clear that we would
not hit our original sales targets, we needed to take measures to reduce and
control our cost base to deliver on our operating guidance. Furthermore, we
needed to advance several funding and business initiatives to extend our cash
runway. Our activities resulted in a one-off income related to the Nxera Deal
and substantially reduced operating expenses throughout all functions meaning we
delivered a significantly lower operating loss than forecast. With the reduced
cost base, two marketed or close-to-market products, and a rich unencumbered
portfolio of innovative assets, Idorsia entered 2024 in a much stronger
position."
Financial results FY 2023
-------------------------------------------------------------------------------
US GAAP results Fourth
Full Year Quarter
-------------------------------------------------------------------------------
in CHF millions, except EPS (CHF) and number of
shares (millions) 2023 2022 2023 2022
-------------------------------------------------------------------------------
Net revenues 152 97 22 54
-------------------------------------------------------------------------------
Operating expenses (409) (900) (134) (247)
-------------------------------------------------------------------------------
Operating income (loss) (255) (803) (111) (193)
-------------------------------------------------------------------------------
Net income (loss) (298) (828) (117) (193)
-------------------------------------------------------------------------------
Basic EPS (1.67) (4.67) (0.65) (1.09)
-------------------------------------------------------------------------------
Basic weighted average number of shares 178.2 177.4 178.6 177.5
-------------------------------------------------------------------------------
Diluted EPS (1.67) (4.67) (0.65) (1.09)
-------------------------------------------------------------------------------
Diluted weighted average number of shares 178.2 177.4 178.6 177.5
-------------------------------------------------------------------------------
US GAAP net revenue of CHF 152 million in 2023 (CHF 97 million in 2022)
consisted of product sales of QUVIVIQ (CHF 30.9 million) and PIVLAZ (CHF 34.4
million), the one-off impact of the Nxera Deal (CHF 68 million), a CHF 9 million
milestone payment from Santhera, a revenue share from Johnson & Johnson (CHF 5
million) and other contract revenues mainly Mochida (CHF 4 million), and
Neurocrine Biosciences, Inc. (CHF 2 million).
US GAAP operating expenses in 2023 amounted to CHF 409 million (CHF 900 million
in 2022), of which CHF 7 million related to cost of sales (CHF 6 million in
2022), CHF 294 million to R&D expenses (CHF 383 million in 2022) and CHF 392
million to SG&A expenses (CHF 509 million in 2022) CHF 11 million restructuring
charges and a one-off income of CHF 298 million relating to the Nxera Deal.
US GAAP net loss in 2023 amounted to CHF 298 million (CHF 828 million in 2022).
The decrease of the net loss was mainly attributable to the one-off income
related to the Nxera Deal but was also driven by higher revenues and lower
operating expenses throughout all functions.
The US GAAP net loss resulted in a net loss per share of CHF 1.67 (basic and
diluted) in 2023, compared to a net loss per share of CHF 4.67 (basic and
diluted) in 2022.
-------------------------------------------------------------------------------
Non-GAAP* measures Fourth
Full Year Quarter
-------------------------------------------------------------------------------
in CHF millions, except EPS (CHF) and number of
shares (millions) 2023 2022 2023 2022
-------------------------------------------------------------------------------
Net revenues 152 97 22 54
-------------------------------------------------------------------------------
Operating expenses (654) (854) (137) (234)
-------------------------------------------------------------------------------
Operating income (loss) (501) (757) (115) (180)
-------------------------------------------------------------------------------
Net income (loss) (542) (782) (121) (186)
-------------------------------------------------------------------------------
Basic EPS (3.04) (4.41) (0.68) (1.05)
-------------------------------------------------------------------------------
Basic weighted average number of shares 178.2 177.4 178.6 177.5
-------------------------------------------------------------------------------
Diluted EPS (3.04) (4.41) (0.68) (1.05)
-------------------------------------------------------------------------------
Diluted weighted average number of shares 178.2 177.4 178.6 177.5
-------------------------------------------------------------------------------
* Idorsia measures, reports and issues guidance on non-GAAP operating
performance. Idorsia believes that these non-GAAP financial measurements more
accurately reflect the underlying business performance and therefore provide
useful supplementary information to investors. These non-GAAP measures are
reported in addition to, not as a substitute for, US GAAP financial performance.
Non-GAAP net loss in 2023 amounted to CHF 542 million: The CHF 244 million
difference versus US GAAP net loss was mainly due to the one-off effect of the
Nxera Deal (CHF 305 million income), depreciation and amortization (CHF 24
million), share-based compensation (CHF 23 million), restructuring charges (CHF
11 million) and a loss on marketable securities (CHF 4 million).
The non-GAAP net loss resulted in a net loss per share of CHF 3.04 (basic and
diluted) in 2023, compared to a net loss per share of CHF 4.41 (basic and
diluted) in 2022.
Nxera Deal (previously known as Sosei Deal)
In July 2023, Idorsia sold its operating businesses in the Asia-Pacific
(excluding China) region to Sosei Heptares (now known as Nxera Pharma) for a
total consideration of CHF 400 million. The territories within the scope of the
transaction are Australia, Brunei, Cambodia, Indonesia, Japan, Laos, Malaysia,
Myanmar, New Zealand, Philippines, Singapore, South Korea, Thailand, Taiwan, and
Vietnam (hereafter the "Territories").
The Nxera deal includes the sale of Idorsia's Japanese and South Korean
affiliates, the assignment of the license for PIVLAZ (clazosentan) for the
Territories and of the (co-) exclusive license for daridorexant for the
Territories, and the assignment of all potential milestones in connection with
the co-exclusive license for daridorexant granted to Mochida Pharmaceutical for
Japan. The Nxera deal also includes an option for Nxera Pharma to license
cenerimod and lucerastat for development and commercialization in the
Territories, with option fees of CHF 3 million and 7 million, respectively, and
subsequent payment of high-single-digit royalties on net sales in the
Territories.
Cost reduction initiative
In July 2023, Idorsia launched a cost reduction initiative, targeting a
reduction of around 50% in its fixed cost base at headquarters.
Approximately 475 positions at headquarters in Allschwil, Switzerland, were
eliminated through a combination of cancellation of new positions, natural
turnover, non-renewal of temporary positions, and terminations, mainly in
Research & Development and associated support functions. The reduction of
positions resulted in a restructuring charge of CHF 11 million.
The initiative has been concluded, with the reduction of costs becoming fully
effective in early 2024.
Reacquisition of aprocitentan rights
In September 2023, Idorsia reached an agreement to reacquire the development and
commercialization rights for aprocitentan from Johnson & Johnson Innovative
Medicine (formerly known as Janssen Biotech, Inc.). In return, Idorsia will pay
Johnson & Johnson Innovative Medicine a conditional consideration up to a total
cap of CHF 306 million, depending on Idorsia's revenues, as follows:
* 30% of any consideration received by Idorsia from a potential out-licensing
or divestment of aprocitentan,
* 10% of any consideration received by Idorsia from a potential out-licensing
or the divestment of any other Idorsia product, following the first approval
of aprocitentan, and
* low- to mid-single-digit royalties on total group product net sales,
beginning from the quarter after first aprocitentan approval.
Johnson & Johnson Innovative Medicine will retain licenses in the pulmonary
hypertension field.
Liquidity and indebtedness (as of December 31, 2023)
At the end of 2023, Idorsia's liquidity amounted to CHF 145 million.
-------------------------------------------------------------------------
(in CHF millions) Dec 31, 2023 Sep 30, 2023 Dec 31, 2022
-------------------------------------------------------------------------
Liquidity
-------------------------------------------------------------------------
Cash and cash equivalents 145 205 146
-------------------------------------------------------------------------
Short-term deposits - 50 320
-------------------------------------------------------------------------
Total liquidity* 145 255 466
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Indebtedness
-------------------------------------------------------------------------
Convertible loan 335 335 335
-------------------------------------------------------------------------
Convertible bond 796 796 795
-------------------------------------------------------------------------
Other financial debt 162 162 162
-------------------------------------------------------------------------
Total indebtedness 1,293 1,292 1,292
-------------------------------------------------------------------------
*rounding differences may occur
Results Day Center
Investor community: To make your job easier, we provide all relevant
documentation via the Results Day Center on our corporate website:
www.idorsia.com/results-day-center (http://www.idorsia.com/results-day-center).
Human Resources
Idorsia reduced 423 positions worldwide in 2023, bringing the total number of
employees (permanent, post-doc, and apprentices) to 938 (2022: 1,361).
Annual Report
Details of the activities performed in 2023 are available in Idorsia's 2023
Annual Report, consisting of the Business Report, Governance Report,
Compensation Report, Financial Report, and for the first time, Sustainability
Report, at www.idorsia.com/annual-report (http://www.idorsia.com/annual-report).
Note to Shareholders
The Annual General Meeting (AGM) of Shareholders to approve the Annual Report of
the year ending December 31, 2023, will be held on Thursday, June 13, 2024.
In order to vote at the Annual General Meeting, shareholders must be registered
in the company's shareholder register by June 4, 2024, at the latest.
Notes to the editor
About Idorsia
Idorsia Ltd is reaching out for more - We have more ideas, we see more
opportunities and we want to help more patients. In order to achieve this, we
will develop Idorsia into a leading biopharmaceutical company, with a strong
scientific core.
Headquartered near Basel, Switzerland - a European biotech-hub - Idorsia is
specialized in the discovery, development and commercialization of small
molecules to transform the horizon of therapeutic options. Idorsia has a 25-year
heritage of drug discovery, a broad portfolio of innovative drugs in the
pipeline, an experienced team of professionals covering all disciplines from
bench to bedside, and commercial operations in Europe and North America - the
ideal constellation for bringing innovative medicines to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017
and has over 750 highly qualified specialists dedicated to realizing our
ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com (http://www.idorsia.com)
The above information contains certain "forward-looking statements", relating to
the company's business, which can be identified by the use of forward-looking
terminology such as "estimates", "believes", "expects", "may", "are expected
to", "will", "will continue", "should", "would be", "seeks", "pending" or
"anticipates" or similar expressions, or by discussions of strategy, plans or
intentions. Such statements include descriptions of the company's investment and
research and development programs and anticipated expenditures in connection
therewith, descriptions of new products expected to be introduced by the company
and anticipated customer demand for such products and products in the company's
existing portfolio. Such statements reflect the current views of the company
with respect to future events and are subject to certain risks, uncertainties
and assumptions. Many factors could cause the actual results, performance or
achievements of the company to be materially different from any future results,
performances or achievements that may be expressed or implied by such forward-
looking statements. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those described herein as anticipated, believed,
estimated or expected.
 
